Volume 191 - Issue 6

Quality of drug interaction alerts in prescribing and dispensing software

Author:  Ian R Cheong

Med J Aust 2009; 191 (6): 358-359. || doi: 10.5694/j.1326-5377.2009.tb02830.x
Published online: 21 September 2009

To the Editor: I was interested to read the results of Sweidan and colleagues’ study of drug interaction alerts in prescribing and dispensing software.1 I believe their use of the terms “sensitivity” and “specificity” differ from the standard definitions, which are usually:

To test sensitivity and specificity, one requires a dataset that includes positives and negatives. I do not view “minor interactions” as a complete set of negatives, because a complete set of negatives should include a statistically valid number of randomly chosen drug sets without interactions. Minor interactions do not meet my criteria for “negatives” because, to me, a minor interaction is still an interaction that may sometimes be clinically significant. A true negative should meet the test of “never clinically significant”. Some reported minor interactions would meet that test and some would not. I believe sensitivity and specificity data should be reported for both major and minor interaction alerts.

I also believe there should be some alignment of definitions between “drug interaction” research and “adverse drug event” research.3 Bates and colleagues talked about “adverse drug events” and “preventable adverse drug events” in 1995.4 Of most clinical interest are the preventable adverse drug events, which could be minimised by the use of appropriate decision support.5,6

Certainly, there is a need for independent assessment of the quality of electronic prescribing decision support systems. A robust assessment methodology is required to permit potential government regulation of such resources, which are of national and community importance.


Author


References